Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912

Oncologist

Volumn 19, Issue 4, 2014, Pages 358-366

  Takahari, Daisuke ^a   Boku, Narikazu ^b   Mizusawa, Junki ^c   Takashima, Atsuo ^c   Yamada, Yasuhide ^d   Yoshino, Takayuki ^e   Yamazaki, Kentaro ^f   Koizumi, Wasaburo ^g   Fukase, Kazutoshi ^h   Yamaguchi, Kensei ⁱ   Goto, Masahiro ^j   Nishina, Tomohiro ^k   Tamura, Takao ^l   Tsuji, Akihito ^m   Ohtsu, Atsushi ^e  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Yamagata Prefectural Central Hospital   (Japan)

ⁱ SAITAMA CANCER CENTER   (Japan)

^j OSAKA MEDICAL COLLEGE   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^l KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m Kochi Health Sciences Center   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; FLUOROURACIL; HEMOGLOBIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STOMACH CANCER; THROMBOCYTE COUNT; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MALE; NEOPLASM METASTASIS; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84898401248     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0306     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Glimelius B, Hoffman K, Haglund U et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-190.
4. Cunningham D, Starling N, Rao S et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358: 36-46.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24: 4991-4997.
6. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-221.
7. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.
8. Solal-Céligny P, Roy P, Colombat P., et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
9. International MyelomaWorking Group. Criteria for the classification of monoclonal gammopathies, multiplemyeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
10. Goldhirsch A, Wood WC, Gelber RD et al; 10th St. Gallen Conference. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
11. Thompson IM, Ankerst DP, Chi C., et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98: 529-534.
12. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17: 2530-2540.
13. Köhne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5- fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
14. Chau I, Norman AR, Cunningham D et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer- pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403.
15. Lee J, Lim T, Uhm JE et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007;18:886-891.
16. Kim JG, Ryoo B-Y, Park YH et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008; 61:301-307.
17. Koo DH, Ryoo B-Y, Kim HJ et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: Validation and comparison with previous models. Cancer Chemother Pharmacol 2011;68:913-921.
18. Yoshida M, Ohtsu A, Boku N., et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004;34: 654-659.
19. Boku N, Yamamoto S, Fukuda H et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol 2009;10: 1063-1069.
20. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998;1:10-24.
21. Pozzo C, Ohashi Y; on behalf of the GASTRIC project. Meta-analysis of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/adjuvant gastric cancer. J Clin Oncol 2009; 27: 15s(supple; abstr 4550).